Other AML drivers (e.g., EZH2, IDH2, KRAS, and MLL) remained unaffected or reduced during CML progression (Fig. 1A, Table S1). This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.